Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) is a Houston-based clinical-stage biopharmaceutical company established in 2017. The company is dedicated to developing novel anticancer drug candidates aimed at treating primary and metastatic cancers of the brain and central nervous system (CNS). Their lead drug candidate, Berubicin, is a pioneering anthracycline that distinguishes itself by its ability to cross the blood-brain barrier, offering new hope for patients suffering from glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer.
Berubicin has shown promise in initial trials, with the Phase I clinical trial completing successfully. As of now, Berubicin is being evaluated in a potentially pivotal study. The preliminary safety data was presented at the Society of NeuroOncology (SNO) 28th Annual Meeting, highlighting its comparability in patient demographics and safety with the control arm of the study. Encouragingly, the independent Data Safety Monitoring Board (DSMB) recommended the continuation of the trial without modification after a pre-planned interim futility analysis, signifying Berubicin’s acceptable efficacy and safety profile.
The company has also secured several important collaborations and licensing agreements, including partnerships with Houston Pharmaceuticals, Inc., the University of Texas M.D. Anderson Cancer Center, and WPD Pharmaceuticals Inc. These agreements bolster the development pipeline and provide access to cutting-edge research and development facilities.
Financially, CNS Pharmaceuticals is proactive in securing necessary funding for their research endeavors. Recent public offerings and strategic financial management have ensured operational continuity and support for their ongoing clinical trials. Despite the inherent risks and uncertainties of drug development, CNS Pharmaceuticals remains steadfast in their mission to develop effective cancer therapies.
Beyond Berubicin, CNS Pharmaceuticals continues to explore additional drug candidates and therapies to address various CNS oncology indications. The company's commitment to innovation and patient care positions it as a potential leader in the fight against some of the most challenging cancer types.
For more information, please visit www.CNSPharma.com and connect with the company on Twitter, Facebook, and LinkedIn.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the 18th Annual European Life Sciences CEO Forum in Zurich, Switzerland.
The company's CEO, John Climaco, will deliver a presentation on Wednesday, February 26, 2025, at 3:20 PM CET / 9:20 AM EST. Management will also be available for one-on-one meetings with qualified registered investors during the conference.
A video webcast of the presentation will be accessible on-demand through the conference presenters portal for registered attendees. The presentation represents an opportunity for CNS Pharmaceuticals to showcase its developments in primary and metastatic cancer treatments.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, has participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference. CEO John Climaco presented the company's top five investment highlights for 2025. The presentation is now available for viewing on the company's website and through the conference platform.
CNS Pharmaceuticals (NASDAQ:CNSP) has announced a 1-for-50 reverse stock split effective February 21, 2025. The company's stock will continue trading on Nasdaq under the same symbol 'CNSP' but with a new CUSIP number: 18978H409.
The reverse split is primarily aimed at increasing the per-share trading price and achieving compliance with Nasdaq's minimum share price requirements. For every 50 shares currently held, stockholders will receive one share. The company will make cash payments in lieu of fractional shares.
All outstanding warrants and equity-based awards will be proportionally adjusted by dividing underlying shares by 50 and multiplying exercise/conversion prices by 50. The par value remains at $0.001 per share, and the authorized share count stays at 300 million shares.
CNS Pharmaceuticals (NASDAQ:CNSP) announced its participation in the 6th Glioblastoma Drug Development Summit in Boston, MA, from February 18-20, 2025. Chief Medical Officer Sandra Silberman, MD, PhD, will present on February 20 at 10:45 AM ET, discussing novel formulations of anthracycline and taxane that can cross the Blood-Brain Barrier (BBB).
The company's lead program, Berubicin, has shown efficacy in Phase 1 and completed enrollment with 252 patients in its pivotal study versus Lomustine for GBM treatment. Primary analysis data is expected in the first half of 2025. CNS is also advancing TPI 287, an abeotaxane showing significant activity in Phase 1b studies.
The FDA has granted Fast Track Designation for Berubicin, allowing more frequent agency interactions, and Orphan Drug Designation for treating malignant glioma, potentially providing seven years of marketing exclusivity upon NDA approval.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the BIO CEO & Investor Conference in New York, NY.
The company's CEO, John Climaco, is scheduled to present on Monday, February 10, 2025, at 1:15 PM ET in the Royale Room. The conference runs from February 10-11, 2025.
Management will be available for one-on-one meetings with conference attendees, who can schedule meetings through the BIO CEO attendee portal. Interested parties can find additional conference information at bcic.bio.org.
CNS Pharmaceuticals (NASDAQ:CNSP) announces a Virtual Analyst & Investor Day scheduled for December 11th, 2024, from 11:30 AM to 1:00 PM ET. The event will feature discussions on Glioblastoma Multiforme (GBM), an aggressive brain cancer with only 14-16 months average survival post-diagnosis.
The presentation will include key company executives and renowned medical experts: CEO John Climaco, CMO Sandra Silberman, VP of Clinical Operations Zena Muzyczenko, along with KOLs Michael Weller, Samuel Goldlust, and Erin Dunbar.
The agenda includes an overview of Berubicin and its clinical development program, plus discussion of their second asset, TPI 287. The event will be accessible via webcast on the company's website, with replay available for 90 days.
CNS Pharmaceuticals (NASDAQ:CNSP) presented updated results from its ongoing pivotal study comparing Berubicin versus Lomustine in adult patients with recurrent glioblastoma (GBM). The study has enrolled 239 patients, with comparable demographics between treatment arms. Key findings show higher study completion rates in the Berubicin arm (84.7% vs 78.9%) and lower withdrawal rates (11.0% vs 19.7%) compared to Lomustine. Safety profiles were similar between arms, with Berubicin showing slightly higher rates of anemia and neutropenia, while Lomustine had more thrombocytopenia cases. The company expects to report primary analysis data in the first half of 2025.
CNS Pharmaceuticals (NASDAQ:CNSP) announced that its abstract has been accepted for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024), taking place November 21-24, 2024 in Houston, TX. The presentation, titled 'Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs. Lomustine After First-Line Therapy for Glioblastoma Multiforme (GBM)', will be presented by Chief Medical Officer Sandra Silberman, MD, PhD, on November 22, 2024.
CNS Pharmaceuticals (NASDAQ:CNSP) reported Q3 2024 financial results, highlighting progress in its clinical development programs. The company completed enrollment of 252 patients in its pivotal Berubicin GBM study, with primary analysis data expected in H1 2025. Net loss increased to $5.6 million from $4.5 million year-over-year. R&D expenses rose to $4.2 million from $3.4 million. The company strengthened its cash position to $7.0 million, supplemented by post-quarter fundraising of $4.6 million, extending operations through Q2 2025. Additionally, CNS expanded its pipeline by in-licensing TPI 287, a late-stage brain malignancy treatment.
CNS Pharmaceuticals (NASDAQ:CNSP) announced its participation in a Virtual Investor KOL Connect segment featuring Professor Michael Weller, Chairman of the Department of Neurology at the University Hospital in Zurich and National Coordinating Investigator for CNS's Berubicin study. The segment focused on glioblastoma multiforme (GBM), discussing unmet medical needs, current treatments, and Berubicin's potential as a solution for this condition.
FAQ
What is the current stock price of CNS Pharmaceuticals (CNSP)?
What is the market cap of CNS Pharmaceuticals (CNSP)?
What is CNS Pharmaceuticals' primary focus?
What is Berubicin?
What makes Berubicin different from other cancer treatments?
What stage is Berubicin currently in?
What recent achievements has CNS Pharmaceuticals reported?
Who are CNS Pharmaceuticals' key partners?
What financial steps has CNS Pharmaceuticals taken recently?
What designations has the FDA granted to Berubicin?
What is the primary endpoint of the Berubicin study?
How does CNS Pharmaceuticals ensure the accuracy and safety of its trials?
